Table 3.
Selected ongoing trials in cancer vaccines across different cancer types (clinicaltrials.gov, accessed on 1 March 2024).
| Condition | Intervention | Adjuvant | Covt. Identifier | Phase | Status | Enrollment |
|---|---|---|---|---|---|---|
| mRNA vaccine | ||||||
| Advanced melanoma | Neoantigen mRNA Pembrolizumab |
- | NCT05933577 | III | Recruiting | 1089 |
| TriMix DC (MAGE-A3, MAGE-C2, tyrosinase and gp100) Ipilimumab |
CD70, CD40 ligand, TLR4 | NCT01302496 | II | Recruiting | 39 | |
| Neoantigen mRNA Pembrolizumab |
-- | NCT03815058 | II | Recruiting | 131 | |
| Resected Stage II (High Risk) and Stage III CRC | Neoantigen mRNA Pembrolizumab |
- | NCT04486378 | II | Recruiting | 201 |
| Unresectable recurrent or metastatic HPV16+ HNSCC | HPV 16 E6 and E7 mRNA Pembrolizumab |
- | NCT04534205 | II | Recruiting | 285 |
| NSCLC | NY-ESO-1, MAGEC1, MAGEC2, 5 T4, survivin, and MUC1 mRNA Durvalumab |
- | NCT03164772 | I/II | Recruiting | 61 |
| Advanced malignant solid tumors. | Neoantigen mRNA | - | NCT05198752 | I | Recruiting | 30 |
| DNA vaccine | ||||||
| Advanced hepatocellular carcinoma | Neoantigen DNA | Plasmid Encoded IL-12 | NCT04251117 | I/IIa | Recruiting | 36 |
| CRC | OncoMimics™ peptides, UCP2 Nivolumab |
Montanide | NCT05350501 | II | Recruiting | 34 |
| Resectable HPV Type 16- and/or 18-positive head and neck cancer | HPV16/18 E6/E7 DNA | Flt3L | NCT05286060 | II | Recruiting | 25 |
| Early stage TNBC | MDM2, YB1, SOX2, CDC25B, CD105 plasmid | GM-CSF | NCT05455658 | II | Recruiting | 33 |
| Peptide vaccine | ||||||
| IIIC-IV melanoma or hormone receptor-positive Her2-negative metastatic refractory breast cancer | Neoantigen peptide Nivolumab |
Poly ICLC | NCT05098210 | I | Recruiting | 20 |
| Advanced solid tumor | Neoantigen peptide Pembrolizumab |
-- | NCT05269381 | I | Recruiting | 36 |